475 related articles for article (PubMed ID: 33348915)
1. PharmFrag: An Easy and Fast Multiplex Pharmacogenetics Assay to Simultaneously Analyze 9 Genetic Polymorphisms Involved in Response Variability of Anticancer Drugs.
Bouvet R; Verdier MC; El Baroudi Y; Galibert MD; David V; Schutz S; Tron C
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348915
[TBL] [Abstract][Full Text] [Related]
2. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
[TBL] [Abstract][Full Text] [Related]
3. A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in
Tron C; Bouvet R; Verdier MC; Lamoureux F; Hennart B; Dubourg C; Bellissant E; Galibert MD
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631462
[TBL] [Abstract][Full Text] [Related]
4. Diversity of oncopharmacogenetic profile within Spanish population.
Ferrer Bolufer I; Galiana Vallés X; Izquierdo Álvarez S; Serrano Mira A; Guzmán Luján C; Safont Aguilera MJ; González Tarancón R; Bolaños Naranjo M; Carrasco Salas P; Santamaría González M; Rodríguez-López R
Pharmacogenet Genomics; 2024 Jul; 34(5):166-169. PubMed ID: 38488402
[TBL] [Abstract][Full Text] [Related]
5. The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
[TBL] [Abstract][Full Text] [Related]
6. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
[TBL] [Abstract][Full Text] [Related]
8.
Moradveisi B; Muwakkit S; Zamani F; Ghaderi E; Mohammadi E; Zgheib NK
Front Pharmacol; 2019; 10():916. PubMed ID: 31507415
[No Abstract] [Full Text] [Related]
9. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.
Mhandire DZ; Goey AKL
Mol Diagn Ther; 2022 Mar; 26(2):137-151. PubMed ID: 35113367
[TBL] [Abstract][Full Text] [Related]
10. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.
Bertholee D; Maring JG; van Kuilenburg AB
Clin Pharmacokinet; 2017 Apr; 56(4):317-337. PubMed ID: 27641154
[TBL] [Abstract][Full Text] [Related]
11. APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Soltysova A; Minarik G; Dzurenkova A; Sufliarska S; Kadasi L; Turna J; Mladosievicova B
Pharmacogenomics; 2011 Apr; 12(4):577-92. PubMed ID: 21521029
[TBL] [Abstract][Full Text] [Related]
12. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.
Ranasinghe P; Sirisena N; Vishnukanthan T; Ariadurai JN; Thilakarathne S; Priyadarshani CDN; Bhagya Hendalage DP; Dissanayake VHW
BMC Med Genomics; 2024 May; 17(1):143. PubMed ID: 38789983
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon.
Ferreira GMA; Ribeiro Elias AB; Nascimento J; Monteiro WM; Melo GC; Baia-da-Silva DC; Lacerda MVG; Suarez-Kurtz G
Pharmacogenet Genomics; 2020 Oct; 30(8):184-189. PubMed ID: 32453263
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacogenetics of anticancer drugs].
de Chaisemartin L; Loriot MA
Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
[TBL] [Abstract][Full Text] [Related]
15. Population impact of pharmacogenetic tests in admixed populations across the Americas.
Suarez-Kurtz G
Pharmacogenomics J; 2021 Apr; 21(2):216-221. PubMed ID: 33110249
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Direct Sequencing, Real-Time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) Analysis for Genotyping of Common Thiopurine Intolerant Variant Alleles NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C).
Fong WY; Ho CC; Poon WT
Diagnostics (Basel); 2017 May; 7(2):. PubMed ID: 28498350
[TBL] [Abstract][Full Text] [Related]
18. Hydrogel microarray for detection of polymorphisms in the UGT1A1, DPYD, GSTP1 and ABCB1 genes.
Heydarov R; Titov S; Abramov M; Timofeev E; Mikhailovich V
Cancer Biomark; 2017; 18(3):265-272. PubMed ID: 28085011
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and pharmacogenomics of anticancer agents.
Huang RS; Ratain MJ
CA Cancer J Clin; 2009; 59(1):42-55. PubMed ID: 19147868
[TBL] [Abstract][Full Text] [Related]
20. Advances and challenges in hereditary cancer pharmacogenetics.
Cascorbi I; Werk AN
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):73-82. PubMed ID: 27603572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
